IL23R and inflammatory bowel disease: In fact, Jürgens et al. found that IL-23R SNPs (rs1004819, rs2201841, rs10889677, rs11209032, and rs1495965), which determine an increased risk of developing IBD, were also associated with an increased infliximab response rate compared to variants which determined a reduced risk of developing IBD (rs7517847, rs10489629, rs11465804, and rs1343151) (74.1% vs. 34.6% p = 0.001) [33].